Canadian newcomer Liphorus sets sights on oral PCSK inhibitors
This article was originally published in Scrip
Executive Summary
A new company, Liphorus Pharmaceuticals, has been spun out of Canada's IRCM (Institut de recherches cliniques de Montréal) to develop small-molecule drugs that inhibit PCSK9 for the treatment of high cholesterol.